PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA.\', \'University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD, 21201, USA.\', \'Department of Pathology, Division of Comparative Medicine, University of Oklahoma, Health Sciences Center, 940 Stanton L. Young, BMS 203, Oklahoma City, OK, 73104, USA.\', \'Catalent Cell & Gene Therapy, 20 Firstfield Road, Gaithersburg, MD, 20874, USA.\', \'Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX, USA.\', \'Novavax AB, Kungsgatan 109, SE-753 18, Uppsala, Sweden.\', \'Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA. GSmith@Novavax.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41467-020-20653-8
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 33446655
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33446655>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33446655>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all